Zoetis Inc.
—- Market cap
- $31.33B
- Debt
- +$9.04B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 78% equity / 22% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $31.33B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: ZTS stock price at discount vs ROIV $75.81 current versus $69.98K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Implied fair value · at ZTS's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ZTS FY 2025 (ended Dec 31, 2025) · ROIV FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 78% equity / 22% debt
Capital structure 98% equity / 2% debt · EV / Revenue 2584.97x
ZTS carries the larger enterprise value at $40.37B against $21.35B; ZTS trades on the lower EV / Revenue multiple (4.26x vs 2584.97x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Zoetis Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
2.71x
0.09x
Net debt / EBITDA
Leverage against operating earnings
—
24.52x
Cash and equivalents
Liquid reserves on the balance sheet
—
$4.29B
Total debt
Interest-bearing obligations outstanding
$9.04B
$412.94M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
ZTS vs PFE
Merck & Co., Inc.
ZTS vs MRK
JOHNSON & JOHNSON
ZTS vs JNJ
ELI LILLY & Co
ZTS vs LLY
Revolution Medicines, Inc.
ZTS vs RVMD
INCYTE CORP
ZTS vs INCY
Sarepta Therapeutics, Inc.
ZTS vs SRPT
EXELIXIS, INC.
ZTS vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ZTS vs VRTX
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.